Muutke küpsiste eelistusi

E-raamat: Sterile Drug Products: Formulation, Packaging, Manufacturing and Quality [Taylor & Francis e-raamat]

  • Taylor & Francis e-raamat
  • Hind: 281,59 €*
  • * hind, mis tagab piiramatu üheaegsete kasutajate arvuga ligipääsu piiramatuks ajaks
  • Tavahind: 402,26 €
  • Säästad 30%
Sterile Drug Products: Formulation, Packaging, Manufacturing, and Quality teaches the basic principles of the development and manufacture of high quality sterile dosage forms. The author has 38 years of experience in the development and manufacture of sterile dosage forms including solutions, suspensions, ophthalmics and freeze dried products. This book is based on the courses he has delivered for over three decades, to over 3000 participants, and is intended to remain relevant for the indefinite future even as new technologies and new applications of old technologies become common.

This is an ideal reference book for those working directly and indirectly with sterile dosage forms, be it product development (formulation, package, process, analytical), manufacturing, quality control, quality assurance, regulatory, purchasing, or project management. This book is also intended as an educational resource for the pharmaceutical and biopharmaceutical industry and pharmacy schools, providing basic knowledge and principles in four main areas of parenteral science and technology:











Product development, including formulation, packaging, and process development.





Manufacturing, including basic teaching on all the primary unit operations involved in preparation of sterile products and the underlying importance of contamination control.





Quality and regulatory, including the application of good manufacturing practice regulations, aseptic processing guidelines, and unique quality control testing methods for the sterile dosage form





Clinical aspects, including administration, potential hazards, and biopharmaceutics of sterile products in a clinical setting.
Preface v
Acknowledgments vii
1 Introduction, scope, and history of sterile products
1(10)
2 Characteristics of sterile dosage forms
11(9)
3 Types of sterile dosage forms
20(9)
4 Sterile product packaging systems
29(19)
5 Overview of product development
48(10)
6 Formulation components (solvents and solutes)
58(14)
7 Sterile products packaging chemistry
72(24)
8 Formulation and stability of solutions
96(19)
9 Dispersed systems
115(23)
10 Formulation of freeze-dried powders
138(31)
11 Overcoming formulation problems and some case studies
169(11)
12 Overview of sterile product manufacturing
180(14)
13 Contamination control
194(17)
14 Sterile manufacturing facilities
211(10)
15 Water and air quality in sterile manufacturing facilities
221(15)
16 Personnel requirements for sterile manufacturing
236(11)
17 Sterilization methods in sterile product manufacturing
247(20)
18 Sterile filtration
267(11)
19 Sterile product filling, stoppering, and sealing
278(16)
20 Freeze-dry (lyophilization) processing
294(19)
21 Aseptic processing
313(15)
22 Inspection, labeling, and secondary packaging
328(18)
23 Barrier and other advanced technologies in aseptic processing
346(16)
24 Stability, storage, and distribution of sterile drug products
362(10)
25 Good manufacturing practice
372(10)
26 Quality assurance and control
382(18)
27 Microorganisms and sterility testing
400(15)
28 Pyrogens and pyrogen/endotoxin testing
415(19)
29 Particles and particulate matter testing
434(21)
30 Sterile product-package integrity testing
455(18)
31 Administration of injectable drug products
473(8)
32 Clinical hazards of injectable drug administration
481(5)
33 Biopharmaceutical considerations with injectable drug delivery
486(9)
Index 495
Michael J. Akers Ph.D. is Senior Director of Pharmaceutical Research and Development at Baxter and leads the Baxter Lyophilization Center of Excellence in Bloomington, Indiana. Dr. Akers received his B.A. degree from Wabash College and Ph.D. degree in Pharmaceutics from the University of Iowa College of Pharmacy, and has previously been employed at Searle Laboratories, Alcon Laboratories, University of Tennessee, and Eli Lilly and Company. Dr. Akers is active in the Parenteral Drug Association and is a Fellow of the American Association of Pharmaceutical Scientists. He is editor-in-chief of Pharmaceutical Development and Technology, and author or editor of six books, including Parenteral Quality Control: Sterility, Pyrogen, Particulate, and Packaging Integrity Testing, Third Edition, 2002.